DHX33 inhibitors induced transcriptional changes for a subset of genes in cancer cells Authors: Xingshun Wang, Yichu Fu, Xiyu Tang, Yandong Zhang Published: 2026 ABSTRACT AbstractRNA helicase DHX33 has been shown to regulate many genes involved in cancer development. Whether or not this depends on its helicase activity remains a question. Two previously developed small molecules, BCD38 and KY386, have been shown to inhibit DHX33 helicase activity in vitro. Of them, KY386 is more potent to inhibit cancer development in vitro and in vivo. In this study, BCD38 and KY386, were both used to evaluate gene transcriptional changes upon DHX33 helicase inhibition. The effect was then compared to that of DHX33 knockdown. What was found was that DHX33 inhibitors caused transcriptional changes for a subset of genes, which recapitulated DHX33 knockdown in human cancer cells, albeit with some discrepancy. DHX33 inhibitors selectively downregulated a subset of genes involved in cancer progression in vitro and in vivo. Our study for the first time reveals that specific targeting DHX33 helicase activity with small molecule inhibitors induced gene transcriptional changes, which mimicked the effect the DHX33 knockdown, implicating that the cellular functions of DHX33 is dependent on its helicase activity.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55801-5.Keywords: DHX33, RNA helicase, Inhibitor, Lung cancer, OncogeneSubject terms: Biochemistry, Cancer, Drug discovery, Molecular biology Introduction RNA helicases are enzymes that utilize the energy derived from ATP hydrolysis to modulate the structures of RNA/DNA molecules1,2, playing crucial roles in various cellular activities such as immunity3–5, embryo development6,7 and tumorigenesis1,8. The DEAD/H-box helicases are the largest family of RNA helicases, characterized by the presence of the conserved DEAD/H motif, playing various roles in RNA metabolism and gene regulation9–11. A few RNA helicases have altered expression levels in human cancers and play indispensable roles during cancer development12–15. DHX33, a member of the DEAH-box family of RNA helicases, has emerged as a significant regulator in cell proliferation through its roles in ribosome biogenesis, mRNA transcription or translation16–19. Genetic deletion of DHX33 is embryonic lethal due to its pivotal roles in cell proliferation during specific organ development6. Additionally, DHX33 has been found to be involved in a complex cascade of events leading to cancer development. For instance, DHX33 has been implicated in the regulation of numerous genes involved in tumorigenesis, such as cell proliferation, survival, and metastasis17,20–26. However, whether or not the helicase activity of DHX33 is responsible for its regulatory roles on these genes remains poorly understood. To address this question, small molecules capable of inhibiting the helicase activity of DHX33 were developed. Two such small molecules, BCD38 and KY386, have been demonstrated to suppress the helicase activity of DHX33 in vitro, albeit with different potency. KY386 has been shown to have a more pronounced effect in inhibiting cancer development in vitro and in vivo27. In this study, both BCD38 and KY386 were employed to assess the changes of mRNA transcription after inhibition of DHX33 helicase activity. The effects of these inhibitors on gene transcription were then compared to the effects of DHX33 knockdown. The comparison between these two different circumstances revealed that inhibitors of DHX33 induced similar changes in gene transcription, recapitulating the effect caused by DHX33 knockdown in human cancer cells. Additionally, the inhibitors selectively downregulated a subset of genes that are involved in cancer progression in vivo. This study, for the first time, directly compared the different effects caused by DHX33 helicase inhibition to DHX33 knockdown on cancer cells, especially on DHX33 regulated gene transcription. The results indicate that DHX33 exerts its cellular functions depending on its helicase activity, which supports the development of future inhibitors targeting DHX33 as novel cancer therapy. Materials and methods Cell culture H1299, A549 lung cancer cell lines were purchased from ATCC. These cells lines were maintained in RPMI-1640 medium containing 10% fetal bovine serum (FBS), 2 mM L-Glutamine and streptomycin and penicillin. U251-MG cells were cultured in MEM medium supplemented with non-essential amino acids, penicillin and streptomycin. HEK293T cells were purchased from ATCC and maintained in DMEM medium with 10% FBS and streptomycin/penicillin. Lentivirus production To produce lentivirus, pLKO.1-shRNA and virus packaging plasmid pCMV-VSV-G and pCMV△R8.2 were transfected into HEK293T cells by Lipofectamine 2000 reagent (Life Technologies). The shRNA sequence targeting human DHX33 has been described previously6. Forty-eight hours later, culture supernatant was collected and centrifuged at 2000 rpm for 2 min. Virus was then aliquoted and frozen at −80 °C. RNA sequencing A549 cells were infected by lentivirus encoding shScrambled or #2-shDHX33, or treated with DHX33 inhibitor, with DMSO as a control. Three days post treatment, cells were harvested, and total RNA was extracted by Nucleospin RNA II kits. RNA samples were then further purified with magnetic oligo-dT beads after denaturation. Purified mRNA samples were reversely transcribed into first strand cDNA, the second complementary DNA was further synthesized. Fragmented DNA samples were then blunt ended and adenylated at 3’ ends. Adaptors were ligated to construct library. DNA was quantified by Qubit (Invitrogen). After cBot cluster generation, DNA samples were then sequenced by Ilumina HiSeq2500 SBS from Genergy Bio (Shanghai). Raw data were converted into Fastq format. The amount of transcripts in each sample is calculated based on FPKM- fragments per kilobase of transcript per million fragments mapped, cuffnorm software is used to calculate the FPKM value for each sample and log 2 value is applied. Cuffdiff software is used to calculate the differential gene transcripts between different samples. False Discovery Rate (FDR) is calculated based on widely recognized Benjamini–Hochberg correction method, and FDR is ultimately used as the key indicator for screening differentially expressed genes. FDR < 0.01 is taken as the default standard. Western blot Cells were lysed by RIPA buffer supplemented with protease and phosphatase inhibitors (Thermo fisher). After incubation for 10 min on ice, cell lysates were further disrupted by sonication. Whole cell extract was then subjected to SDS-PAGE with a loading amount of 50 µg protein per sample. Proteins were then transferred onto a polyvinylidene difluoride membrane. Membranes were blocked in 5% nonfat milk which was diluted in 1 × TBST buffer for 1 h at room temperature. Primary antibodies which were diluted in 5% FBS (diluted in 1 × TBST) were incubated with the membrane at 4 °C overnight. Membranes were then rinsed with 1 × TBST buffer for multiple times and incubated with HRP-labeled secondary antibodies in 5% FBS (diluted in 1 × TBST) at room temperature for 2 h. Blots are visualized with an ECL kit (Thermo fisher). The antibodies were sourced as follows: anti-GAPDH, Absin (abs830030); anti-DHX33, Bethyl (A300-800A); anti-DHX33, Santa Cruz Biotechnology (B-4, sc-390573); anti-Aurora A, Santa Cruz Biotechnology (sc-56881); anti-MCM2, Santa Cruz Biotechnology (sc-9839); anti-MCM3, Santa Cruz Biotechnology (sc-9850); anti-MCM4, Santa Cruz Biotechnology (sc-22779); anti-MCM6, Santa Cruz Biotechnology (sc-9843); anti-MCM7, Santa Cruz Biotechnology (sc-9960); anti-cyclin D1, Santa Cruz Biotechnology (sc-753); anti-cyclin B2, Santa Cruz Biotechnology (sc-22776). Quantitative real-time PCR The primers were all designed by IDT (http://sg.idtdna.com/site) online “Realtime PCR Tool” and purchased from BGI (Shenzhen). Total RNA was extracted by High Pure RNA Isolation kit (Roche) and then transcribed into cDNA using PrimeScript mix kit (Takara). Real-time PCR is performed with an ABI One step plus cycler that is managed with the corresponding software. To analyze mRNA levels, SYBR green Supermix (Bio-Rad) was used, and transcript quantification was calculated by △△CT value after normalized to GAPDH values. Melting curve was used to confirm the amplification of single product. Primers for analysis of cell cycle related genes were used based on previous studies6. Growth curve analysis Approximately 1.0 × 104 cells were plated onto 12-well dish. Cells were then counted by a hemocytometer on a daily basis, each condition were counted three times. Foci analysis Cells were plated at a density of 104 per 100-mm dish and grown for 10 to 20 days. Colonies were washed with cold phosphate-buffered saline twice and fixed with 100% methanol for 10 min at room temperature. Colonies were then stained with Giemsa stain for 1 h at room temperature and washed with water before air-dried and photographed. Transwell migration assay Transwell Migration assay plates (8 m) were purchased from Corning (Shenzhen, China), standard protocol was followed according to manufacturer’s protocol. Briefly, 1.0 × 104 cells were suspended in MEM media containing 0.25% FBS on the top container which was submerged into complete MEM media containing 10% FBS. Cells were allowed to culture overnight. The next morning, membrane was removed, all the cells inside the well was rubbed off, the cells that penetrate the membrane was either stained by Giemsa or by DAPI before photographing under the microscope. Soft agar assay 1.0 × 104 cells were mixed in 4.0 mL 0.3% agar/DMEM/10% FBS as the top agar and plated into 60 mm plates with 4.0 mL 0.6% agar/DMEM/10% FBS as the base agar. Plates were incubated at 37 °C, checked every 3 days, and fed with 2.0 ml 0.3% agar/DMEM/10% FBS every week. Colonies were photographed and counted 2–3 weeks later. Mouse xenograft models The animal study was approved by the Ethical Committee in KeYe Life Technolgies Co., Ltd. All animal handling and experimental procedures involving mice were conducted in strict accordance with Regulations of Guangdong Province on the administration of laboratory animals. Female Balb/c nude mice, aged 4 to 6 weeks and weighing between 18 and 25 g, were procured from Beijing Vital River Laboratory Animal Technology Co., Ltd., where they were provided with standard care as per institutional protocols. A cohort of ten mice was randomly assigned to two distinct groups. For the injection into the nude mice, both U251-MG and A549 cell lines were treated with trypsin and then resuspended in 200 µl of DMEM medium to achieve a density of 1 × 10^8 cells per milliliter. Subcutaneous injections of 1 × 10^7 cells were administered along the flanks of the nude mice6. When tumors appeared palpable, they were randomly divided into two groups, each group contains 5 mice. KY386 was administrated at a dose of 50 mg/kg with intraperitoneal injection. Cervical dislocation was performed on all mice on Day 18 post-injection. Subsequently, the tumors were harvested, their weights recorded, and photographs were taken for documentation. Immunohistochemistry (IHC) The tissue sections on slides underwent deparaffinization in xylene and subsequent rehydration through a graded ethanol series. Antigen retrieval was performed in a Tris buffer solution at a pH of 9.0, utilizing a steaming process. To quench endogenous peroxidase activity, the sections were treated with a 1% hydrogen peroxide solution in methanol for a duration of 30 min. Following this, a 1-h pre-incubation period with 10% normal fetal bovine serum was conducted to minimize nonspecific background staining. The primary antibody was then introduced and allowed to bind to the samples at ambient temperature for a period of 2 h. Subsequently, a standard immunohistochemical protocol was adhered to, employing a Dako EnVision detection kit with a polymer to enhance signal detection. The immunoreactivity, in terms of both staining intensity and the proportion of positively stained cells across various regions of the slide, was quantified using previously established criteria23,28. The antibody used were sourced as follows: anti-Ki 67, Abcam (ab15580); anti-HMGCR ABclonal (A16875); anti-DHX33, Santa Cruz (B4). Statistical analysis Data are presented as the mean ± SD. Statistical significance was determined using the Student’s t test, with a P value < 0.05 considered significant. Results DHX33 inhibitor BCD38 caused similar transcriptome changes as DHX33 knockdown Previously we have reported the identification of a small molecule inhibitor, BCD38, targeting the helicase activity of DHX33 through high-throughput screening27. To analyze the changes in gene transcription after BCD38 treatment in cells, and to investigate how well DHX33 inhibitor mimicked DHX33 knockdown, RNA-sequencing analysis was performed. A549 cells were either treated with BCD38 or were infected with lentiviruses encoding shDHX33 to knockdown DHX33. The change of transcriptome after BCD38 treatment was compared to the change of the gene transcription after DHX33 knockdown. The full dataset for this RNA sequencing analysis is shown in the Supplemental Table S1. The heatmap is shown in Fig. 1A. We found that the changes of genes in the BCD38 treatment group exhibited similar trend as the DHX33 knockdown group but less efficiently. BCD38 was not as potent as acute DHX33 knockdown, as only a small subset of genes had altered expression after BCD38 treatment while DHX33 knockdown caused nearly 2000 genes to be changed as compared to the control group. The differential gene expression patterns are shown in the volcano plots of Fig. 1B. A subset of genes involved in cell cycle have been shown to be regulated by DHX33 before6. The expression levels of these genes as evaluated by RNA-sequencing in FPKM values and the fold changes were shown in Fig. 1C. The changes of the designated target genes in the inhibitor group have the same trend as the DHX33 knockdown group, but with a lower efficiency. Scattered plot analysis demonstrated that there is significant correlation for gene expression (as shown in Fig. 1C) under these two conditions (Fig. 1D). DHX33 inhibitor BCD38 caused similar transcriptome changes as DHX33 knockdown. (A) A549 cells with DHX33 knockdown (shSCR was used as a control) or BCD38 treatment (DMSO was used as a control) were extracted for total RNA and then subjected to RNA-seq analysis. Heatmap is shown for altered genes with a side to side comparison. (B) Volcano plots for differential gene expression changes between these two groups. (C) The expression levels of a subset of genes involved in cell cycle progression by RNA-sequencing analysis. (D) Scattered plot for correlation analysis for genes listed in (C) in the different contexts, DHX33 knockdown and DHX33 inhibitor treatment. Each dot represents one single gene. The RNA sequencing information may be available in GEO database in time. BCD38 inhibits cell proliferation, cell survival, anchorage-independent growth and cell migration DHX33 has been found to promote cancer development in vitro and in vivo, through regulating a subset of genes involved in cancer progression20–26. As BCD38 caused similar effects as DHX33 knockdown, BCD38 was then analyzed for its potency in cytotoxicity with a few lung cancer cell lines. Firstly, cell proliferation index was analyzed with two different lung cancer cell lines, A549 and H1299. As shown in Fig. 2A, in both cancer cell lines, BCD38 treatment caused decreased cell proliferation. Next, the anchorage independent cell growth was analyzed by soft agar analysis. After BCD38 treatment, 3-dimentional cell growth inhibition was observed in A549, H1299 lung cancer cell lines (Supplemental Figure S1). Statistical analysis demonstrated that there was a significant difference. We further analyzed the cell migration. In both A549 and H1299 cancer cell lines, BCD38 decreased cell migration (Supplemental Figure S2). To find out whether BCD38 downregulated genes similarly as DHX33 knockdown, we further analyzed the protein levels for a few representative genes which have been proved to be regulated by DHX33 before6. The expression of MCMs and cyclins genes was firstly evaluated in H1299 cells either after BCD38 treatment or after DHX33 knockdown. As shown in Fig. 2B (left), the protein levels of these genes were decreased. Next, to confirm these results, the protein expression of these genes was further analyzed in A549 cells by western blot. They were found to be down-regulated by DHX33 inhibitor BCD38 or DHX33 knockdown. BCD38 inhibits cell proliferation, cell survival, anchorage-independent growth and cell migration. (A) Left: Growth curves for a panel of lung cancer cell lines in the presence of BCD38 treatment. Middle: Anchorage independent growth of a panel of cancer cell lines in the presence of BCD38. *, P < 0.05, n = 3. Right: Cell migration analysis for lung cancer cell lines in the presence of BCD38 treatment. *, P < 0.05, n = 3. (B) H1299 cells were either transduced by lentivirus to knockdown DHX33 (left) or treated with DHX33 inhibitor, the expression of the designated genes were analyzed by Western blot, GAPDH serves as an internal control. A549 cells were either transduced by lentivirus to knockdown DHX33 (left) or treated with DHX33 inhibitor, the expression of the designated genes were analyzed by Western blot, GAPDH serves as an internal control. The blots shown in the figure were cropped from the original raw western blot data which were provided in the Supplemental information. (C)The chemical structures for BCD38 and KY386 (D) A549 cells were treated with DHX33 inhibitor KY386, the expression of the designated genes were analyzed by Western blot, GAPDH serves as an internal control. The blots shown in the figure were cropped from the original raw western blot data which were provided in the Supplemental information. Given moderate cytotoxicity was observed for cancer cells after BCD38 treatment, we switched to a more potent inhibitor of DHX33, KY386, for functional studies. The chemical structures for BCD38 and KY386 were shown in Fig. 2C. KY386 has been found to be more potent in inhibiting the helicase activity of DHX33 in vitro and in cells29. To confirm that KY386 functioned similarly as BCD38 in inhibiting DHX33 to cause the downregulation of DHX33 target genes, we performed western blot analysis after applying different concentrations of KY386 onto A549 cells. The results are shown in Fig. 2D, both cyclins and MCMs were downregulated. KY386 phenocopied DHX33 knockdown to regulate genes in cancer cells To investigate whether KY386 regulated DHX33 target genes similarly in cancer cells, both DHX33 knockdown and KY386 treatment were performed in cancer cells. For this experiment, specific set of genes involved in mevalonate pathway were analyzed in cancers. Previously, DHX33 has been found to regulated multiple genes involved in the mevalonate pathway, and thereby contribute to cancer cell proliferation. As shown in Fig. 3A, U251-MG cell was used as a model system. These cells were deprived of lipid through serum starvation30. As compared to cells incubated with serum, significant upregulation of mevalonate genes was observed. When 25-OH-cholesterol was supplemented into the serum free media, all of these upregulated genes were downregulated to basal levels. When DHX33 was knocked down under lipid free condition, many mevalonate pathway genes were downregulated, except for PMVK, SREB and RPL3229. These data implicated that DHX33 was specific in regulating a subset of genes to promote cell proliferation. Under serum starvation conditions, U251-MG cells were then treated with either KY386 or 25-OH-cholesterol alone, or both in combination. The changes of the transcription levels were then analyzed by quantitative PCR analysis and the results were shown in Fig. 3A. Importantly, KY386 similarly caused marked downregulation of genes which were regulated by DHX33 knockdown, except for PMVK, SREB and RPL32, which were shown to have limited or no reduction in transcription levels. Scattered plot analysis for the genes mentioned in Fig. 3A further demonstrated that there is significant correlation for the designated gene expression under these two different conditions (Fig. 3B). Our results confirmed that KY386 and DHX33 knockdown functioned similarly to reduce the expression of specific genes in cancer cells. KY386 phenocopied DHX33 knockdown to regulate genes in cancer cells (A) U251-MG cells were either serum starved, or treated with serum free media but supplemented with 25-OH-cholesterol (1 μM), for 24 h, cells were then either treated with KY386 at 25 nM, with DMSO as control for 6 h. Total RNA was then isolated for QPCR analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, n = 3.(B)Scattered plot for correlation analysis for mevalonate pathway genes in the different contexts, DHX33 knockdown and DHX33 inhibitor treatment. Each dot represents one single gene in the mevalonate pathway. KY386 caused the downregulation of genes involved in mevalonate pathway in vivo. To analyze whether KY386 downregulated mevalonate pathway genes in vivo, we set up cell line derived xenograft (CDX) mice models for study. KY386 has been found to inhibit tumor growth in vivo30. For the current study, both U251-MG and A549 cells were used for xenograft models. Cancer cells were injected into the flanks of immunocompromised mice subcutaneously. When tumors reached to the average size of 80 mm3 in volume, mice were treated with KY386 through IP injection twice a day at a dose of 50 mg/kg. Tumor size and mouse body weight were monitored at the indicated time points. Approximately 18 days later, the mice were sacrificed for tumor dissection. Tumor images after dissection were shown in Fig. 4A. The curves of body weight and tumor volume were shown in Fig. 4B-C. KY386 demonstrated similar anti-tumor effect in vivo. After drug treatment, tumor tissue slice were analyzed by immunohistochemistry. The Ki-67 proliferation index was calculated for the tissues. The results are shown in Fig. 4D-E, cell proliferation was significantly reduced. KY386 treatment did not lead to decrease in DHX33 protein levels, however, the protein level of HMGCR was decreased in KY386 treatment group (Fig. 4D-E). Representative tumor xenograft tissues for A549 models were further isolated for total RNA extraction. Quantitative PCR was performed afterwards for a set of genes involved in mevalonate pathway. As shown in Fig. 4F, KY386 caused reduction in the mRNA levels of mevalonate genes as compared to the vehicle controls. The study confirmed that KY386 blocked mevalonate pathway gene expression in vivo. KY386 caused the downregulation of genes involved in mevalonate pathway in vivo (A) Equal numbers of A549 or U251-MG cells were injected into Nude mice subcutaneously to establish xenograft cancer model. When tumors appeared palpable, they were randomly divided into two groups, each group contains 4–5 mice. KY386 was administrated at a dose of 50 mg/kg with introperitoneal injection. Tumor tissues were dissected at the end of experiment and photographed. (B)Tumor size was monitored and plotted during the course of the study. *, P < 0.05, statistically significant difference. (C)Mouse body weight was monitored throughout the experiment and plotted. Changes of the body weight for mice in each group showed that there was no significant difference between two groups. (D)Tumor tissues from U251-MG and A549-xenografts after KY386 treatment were further analyzed by H&E and immunohistochemistry staining. Anti-Ki67 antibody was used to analyze the proliferation index. DHX33 protein and HMGCR protein levels were also analyzed. Representative images are shown with image calibration shown below. (E)The quantitation for Ki-67, DHX33 and HMGCR signals are shown, there is statistically significant difference for Ki-67 and HMGCR between the two different groups, but not for DHX33 protein. ****, P < 0.0001, n = 5. (F)Total RNA was isolated from representative cancer xenografts. QPCR was performed to analyze the transcript levels for genes involved in the mevalonate pathway. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, n = 3. Discussion The family of RNA helicases belongs to RNA binding proteins with important roles in modulating RNA activities in cells1. Despite their importance, their detailed and specific modes of action remain mostly unresolved. Biochemically, these proteins exist in many large cellular machineris, such as ribosome complexes or mRNA splicing complexes, and are much more complex than protein kinases9. Most RNA species have short half-lives, a distinct configuration of RNA molecule confers specific activity in cells. Protein cofactors and specific cellular location play decisive roles in determining how and where they function in cells. RNA helicases have relatively conserved helicase cores consisting of two separate enzymatic centers. One is ATP/NTP hydrolysis activity center, and the other is unwindase/helicase active center for RNA/DNA or RNA/DNA hybrid duplexes1,9. Despite their ATPase core structurally highly resembles one another1, each RNA helicase adopts a distinct conformation and is conferred a distinct specificity in recognizing substrates, possibly through its unique helicase activity center and their protein cofactors, as well as specific cellular context1. Little is known about the necessity of their enzymatic activity for their diverse and specific cellular functions. Up till now, limited helicase inhibitors have been developed successfully toward these proteins for functional probes32–35. DHX33 protein has been to find to associate with gene promoters at the DNA level and to regulate the initiation of mRNA transcription globally23. Specifically, previous findings showed that DHX33 was capable of binding the GC rich domains of gene promoters, it acts together with DNA demethylation proteins to alter the local epigenetic marks and therefore shape the global DNA methylation status23. DHX33 was hypothesized to regulate the formation of R-loop structures in the proximity of gene promoters, though the detailed molecular mechanism remains incompletely resolved. In the present study, for the first time, small molecules inhibiting the helicase activity of DHX33 were utilized to delineate the global changes of gene transcription in cancer cells. What was found was that DHX33 helicase inhibition highly resembled DHX33 gene knockdown in regulating global transcription in cancer cells. Our results indicate that the helicase activity of DHX33 is required for its activity in regulating gene transcription. For the first time, the study gave a convincing proof that targeting the helicase activity of DHX33 has therapeutic potential in inhibiting cancer development. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Acknowledgements We acknowledge all the support from Xianglu Li and the staff from KeYe Life Technologies Co., Ltd, without them, the study could not be completed. Abbreviations DEAH box protein 33 Dulbecco’s modified essential medium Fetal bovine serum Cytomegalovirus Phosphate-buffered saline Tris-buffered saline-tween-20 Quantitative polymerase chain reaction 4',6-diamidino-2-phenylindole Scrambled Sodium dodecyl sulfate-polyacrylamide gel electrophoresis Mouse embryonic fibroblast Ethylenediaminetetraacetic acid Author contributions Conception, supervision and grant acquisition: Y.Z Experiment, data acquisition and analysis: X.W, X.T, Y.F Writing: Y.Z Funding This work was also supported by funds from Shenzhen KeYe Life Technologies Co., Ltd. X.W was supported by the Yunnan Provincial Department of Education Science Research Foundation (Grant No.2024J0764)(X.W.). Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Data Availability Statement No datasets were generated or analysed during the current study.